COMP <GO>
TEVA vs ABBV // NET PROFIT MARGIN
Teva Pharmaceutical Industries Limited (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: TEVA 4
— ABBV 10
▲ NET PROFIT MARGIN LEADER: TEVA
LAST: $41.47 (+3.75%) • MKT CAP: $48.32B
net-margins
8.20%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
net-margins
6.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TEVA VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TEVA | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 51.80% | 70.20% | -18.40 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.40% | 29.00% | -19.60 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.8x | 33.3x | -12.50 | TEVA | /valuation <GO> |
| Free Cash Flow Yield | 1.81% | 3.47% | -1.66 | ABBV | /fcf-yield <GO> |
| Operating Margin | 12.50% | 24.60% | -12.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 8.20% | 6.90% | +1.30 | TEVA | /net-margins <GO> |
| Revenue Growth (YoY) | 4.30% | 8.60% | -4.30 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.02 | 5.33 | -4.31 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | TEVA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.6 | 65.1 | -6.50 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.15 | -0.15 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.9x | 113.1x | -81.20 | TEVA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $48.32B | $513.86B | -$465.54B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TEVA REV | ABBV REV | TEVA GROSS % | ABBV GROSS % | TEVA FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $17.26B | $61.16B | 51.8% | 70.2% | $872.4M | $17.82B |
| FY 2024 | $16.54B | $56.33B | 48.7% | 70.0% | $502.5M | $17.83B |
| FY 2023 | $15.85B | $54.32B | — | — | $654.9M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TEVA // BETA 1.00
ABBV // BETA 1.15